Skip to Content

Conivaptan Disease Interactions

There are 4 disease interactions with conivaptan:

Moderate

Conivaptan (Includes conivaptan) ↔ heart failure

Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure

The amount of safety data on the use of conivaptan in patients with hypervolemic hyponatremia associated with heart failure is limited. Conivaptan should only be used to raise sodium in such patients after consideration of other treatment options. Caution is advised if using in these patients.

Moderate

Conivaptan (Includes conivaptan) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The systemic exposure to unbound conivaptan doubled in subjects with moderate and severe hepatic impairment. Caution is advised in these patients.

Moderate

Conivaptan (Includes conivaptan) ↔ severe renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The use of conivaptan is not recommended in patients with severe renal impairment (CrCl < 30 mL/min), as there is an unlikely benefit. There is also a high incidence of infusion site phlebitis, which can reduce vascular access sites.

Moderate

Vasopressin antagonists (Includes conivaptan) ↔ liver disease/alcoholism

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease, Alcoholism

Osmotic demyelination syndrome is a risk associated with overly rapid correction of hyponatremia (> 12 mEq/L/24 hours). This syndrome can result in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizure, coma or death. Patients with advanced liver disease, alcoholism or severe malnutrition are at increased risk and require slower rates of correction. Serum sodium concentration and neurological status should be monitored appropriately during treatment administration. Vasopressin antagonists should be initiated and re- initiated in patients only in hospital settings were sodium levels can be monitored closely.

Conivaptan drug interactions

There are 512 drug interactions with conivaptan

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide